SK16972000A3 - Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do kapsúl, spôsob výroby kapsúl s obsahom hydrochloridu paroxetínu a súprava zahrnujúca takého kapsuly - Google Patents

Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do kapsúl, spôsob výroby kapsúl s obsahom hydrochloridu paroxetínu a súprava zahrnujúca takého kapsuly Download PDF

Info

Publication number: SK16972000A3
Authority: SK; Slovakia
Prior art keywords: paroxetine hydrochloride; anhydrous; paroxetine; hemihydrate; glycerides
Prior art date: 1998-05-13

Application number

SK1697-2000A

Other languages

English (en)

Slovak (sk)

Inventor

David Philip Elder

Graham Stanley Leonard

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-13

Filing date

1999-05-13

Publication date

2001-06-11

1999-05-13 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-06-11 Publication of SK16972000A3 publication Critical patent/SK16972000A3/sk

Links

AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 61
229960002296 paroxetine Drugs 0.000 title description 16
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title description 15
239000000203 mixture Substances 0.000 title description 4
238000009472 formulation Methods 0.000 title 1
239000002775 capsule Substances 0.000 claims abstract description 28
229960005183 paroxetine hydrochloride Drugs 0.000 claims abstract description 19
238000004519 manufacturing process Methods 0.000 claims abstract description 11
238000006243 chemical reaction Methods 0.000 claims abstract description 6
238000000034 method Methods 0.000 claims description 20
239000000546 pharmaceutical excipient Substances 0.000 claims description 12
125000005456 glyceride group Chemical group 0.000 claims description 10
-1 monosaccharide sugars Chemical class 0.000 claims description 8
238000007907 direct compression Methods 0.000 claims description 7
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
229960004977 anhydrous lactose Drugs 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 5
235000000346 sugar Nutrition 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
239000002274 desiccant Substances 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
150000004665 fatty acids Chemical class 0.000 claims description 3
150000002191 fatty alcohols Chemical class 0.000 claims description 3
239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
230000002209 hydrophobic effect Effects 0.000 claims description 3
235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
239000008158 vegetable oil Substances 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
229920000881 Modified starch Polymers 0.000 claims description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
150000002334 glycols Chemical class 0.000 claims description 2
229920003124 powdered cellulose Polymers 0.000 claims description 2
235000019814 powdered cellulose Nutrition 0.000 claims description 2
235000013311 vegetables Nutrition 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
239000007903 gelatin capsule Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
229960000656 paroxetine hydrochloride anhydrous Drugs 0.000 description 7
239000000725 suspension Substances 0.000 description 7
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 6
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000000832 lactitol Substances 0.000 description 5
235000010448 lactitol Nutrition 0.000 description 5
229960003451 lactitol Drugs 0.000 description 5
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 4
240000002470 Amphicarpaea bracteata Species 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
244000060011 Cocos nucifera Species 0.000 description 2
235000013162 Cocos nucifera Nutrition 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012458 free base Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
241001133760 Acoelorraphe Species 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000219146 Gossypium Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000032683 aging Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
229940074928 isopropyl myristate Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
238000000465 moulding Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920000059 polyethylene glycol stearate Polymers 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

SK1697-2000A 1998-05-13 1999-05-13 Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do kapsúl, spôsob výroby kapsúl s obsahom hydrochloridu paroxetínu a súprava zahrnujúca takého kapsuly SK16972000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9810180.1A GB9810180D0 (en)	1998-05-13	1998-05-13	Novel formulation
PCT/GB1999/001522 WO1999058116A2 (en)	1998-05-13	1999-05-13	Novel formulation containing paroxetine

Publications (1)

Publication Number	Publication Date
SK16972000A3 true SK16972000A3 (sk)	2001-06-11

Family

ID=10831926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1697-2000A SK16972000A3 (sk)	1998-05-13	1999-05-13	Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do kapsúl, spôsob výroby kapsúl s obsahom hydrochloridu paroxetínu a súprava zahrnujúca takého kapsuly

Country Status (20)

Country	Link
EP (1)	EP1077685A2 (xx)
JP (1)	JP2002514593A (xx)
KR (1)	KR20010043545A (xx)
CN (1)	CN1309557A (xx)
AP (1)	AP2000001985A0 (xx)
AU (1)	AU3941099A (xx)
BG (1)	BG105011A (xx)
BR (1)	BR9910402A (xx)
CA (1)	CA2331849A1 (xx)
EA (1)	EA200001173A1 (xx)
GB (1)	GB9810180D0 (xx)
HU (1)	HUP0101931A3 (xx)
ID (1)	ID27018A (xx)
IL (1)	IL139596A0 (xx)
NO (1)	NO20005681L (xx)
PL (1)	PL344872A1 (xx)
SK (1)	SK16972000A3 (xx)
TR (1)	TR200003351T2 (xx)
WO (1)	WO1999058116A2 (xx)
ZA (1)	ZA200006465B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE311883T1 (de)	1999-03-12	2005-12-15	Aesica Pharmaceuticals Ltd	Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
HU226912B1 (en) *	2000-04-07	2010-03-01	Richter Gedeon Nyrt	New paroxetin salt and medicament containing it
WO2013145750A1 (ja) *	2012-03-29	2013-10-03	杏林製薬株式会社	カプセル製剤
DE102013207447A1 (de)	2013-04-24	2014-10-30	Evonik Degussa Gmbh	Verfahren und Vorrichtung zur Herstellung von Octachlortrisilan
CN103520131B (zh) *	2013-10-12	2019-05-14	浙江华海药业股份有限公司	盐酸帕罗西汀半水合物胶囊的制备方法
CN103961333B (zh) *	2014-05-07	2020-02-21	浙江华海药业股份有限公司	甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9707585A (es) *	1995-04-03	1997-12-31	Abbott Lab	Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
GB9724544D0 (en) *	1997-11-21	1998-01-21	Smithkline Beecham Plc	Novel Formulation

1998
- 1998-05-13 GB GBGB9810180.1A patent/GB9810180D0/en not_active Ceased
1999
- 1999-05-13 HU HU0101931A patent/HUP0101931A3/hu unknown
- 1999-05-13 JP JP2000547967A patent/JP2002514593A/ja active Pending
- 1999-05-13 CA CA002331849A patent/CA2331849A1/en not_active Abandoned
- 1999-05-13 EA EA200001173A patent/EA200001173A1/ru unknown
- 1999-05-13 EP EP99922303A patent/EP1077685A2/en not_active Withdrawn
- 1999-05-13 AU AU39410/99A patent/AU3941099A/en not_active Abandoned
- 1999-05-13 AP APAP/P/2000/001985A patent/AP2000001985A0/en unknown
- 1999-05-13 WO PCT/GB1999/001522 patent/WO1999058116A2/en not_active Ceased
- 1999-05-13 KR KR1020007012660A patent/KR20010043545A/ko not_active Withdrawn
- 1999-05-13 BR BR9910402-4A patent/BR9910402A/pt not_active Application Discontinuation
- 1999-05-13 TR TR2000/03351T patent/TR200003351T2/xx unknown
- 1999-05-13 PL PL99344872A patent/PL344872A1/xx unknown
- 1999-05-13 IL IL13959699A patent/IL139596A0/xx unknown
- 1999-05-13 SK SK1697-2000A patent/SK16972000A3/sk unknown
- 1999-05-13 ID IDW20002329A patent/ID27018A/id unknown
- 1999-05-13 CN CN99808548A patent/CN1309557A/zh active Pending
2000
- 2000-11-09 ZA ZA200006465A patent/ZA200006465B/en unknown
- 2000-11-10 NO NO20005681A patent/NO20005681L/no not_active Application Discontinuation
- 2000-11-30 BG BG105011A patent/BG105011A/xx unknown

Also Published As

Publication number	Publication date
ID27018A (id)	2001-02-22
CA2331849A1 (en)	1999-11-18
CN1309557A (zh)	2001-08-22
WO1999058116A3 (en)	2000-02-17
EP1077685A2 (en)	2001-02-28
EA200001173A1 (ru)	2001-04-23
HUP0101931A3 (en)	2002-10-28
TR200003351T2 (tr)	2001-03-21
HUP0101931A2 (hu)	2002-04-29
NO20005681L (no)	2000-12-01
BG105011A (en)	2001-07-31
NO20005681D0 (no)	2000-11-10
PL344872A1 (en)	2001-11-19
AP2000001985A0 (en)	2000-12-31
JP2002514593A (ja)	2002-05-21
BR9910402A (pt)	2001-01-09
ZA200006465B (en)	2001-11-09
GB9810180D0 (en)	1998-07-08
AU3941099A (en)	1999-11-29
KR20010043545A (ko)	2001-05-25
WO1999058116A2 (en)	1999-11-18
IL139596A0 (en)	2002-02-10

Publication	Publication Date	Title
US6491950B1 (en)	2002-12-10	Controlled release pharmaceutical composition
FI117373B (fi)	2006-09-29	Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti
AU748396B2 (en)	2002-06-06	Composition
SK284972B6 (sk)	2006-03-02	Pevná farmaceutická kompozícia obsahujúca deriváty benzofuránu
SK16972000A3 (sk)	2001-06-11	Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do kapsúl, spôsob výroby kapsúl s obsahom hydrochloridu paroxetínu a súprava zahrnujúca takého kapsuly
KR100196308B1 (ko)	1999-06-15	푸란 유도체를 함유하는 제약 조성물
US5705506A (en)	1998-01-06	Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration
US8901128B2 (en)	2014-12-02	Pharmaceutical compositions of ranolazine
US20110196032A1 (en)	2011-08-11	Pharmaceutical Dosage Form of an Antidepressant
SK7342000A3 (en)	2000-12-11	Formulations comprising dissolved paroxetine
PL191767B1 (pl)	2006-06-30	Stabilizowane przed racemizacją stałe lub ciekłe preparaty farmaceutyczne zawierające jako składnik czynny cilansetron, sposób wytwarzania stabilizowanych przed racemizacją stałych preparatów farmaceutycznych zawierających jako składnik czynny cilansetron oraz zastosowanie dopuszczalnych fizjologicznie rozpuszczalnych w wodzie kwaśnych dodatków
AU2003224419A1 (en)	2003-09-09	Orally administrable pharmaceutical formulation
US20020032220A1 (en)	2002-03-14	Formulations comprising dissolved paroxetine
MXPA00011153A (en)	2001-07-31	Novel formulation containing paroxetine
CZ20004185A3 (cs)	2001-05-16	Nový prostředek obsahující paroxetin
KR20010105418A (ko)	2001-11-28	기분 장애 치료용 오사네턴트
US20030050312A1 (en)	2003-03-13	Novel tablets and capsules and a process for its preparation
IL97648A (en)	1995-12-08	Stabilized 4-ethyl-2-hydroxyimono-5-nitro-3-hexenamide pharmaceutical compositions and methods for the preparation thereof
CA2367402C (en)	2010-11-23	Stable pharmaceutical dosage form for paroxetine anhydrate
US5817336A (en)	1998-10-06	Composition containing selegiline
US6926906B2 (en)	2005-08-09	Orally administrable pharmaceutical formulation
CA2537480A1 (en)	2005-03-17	Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof
EA003584B1 (ru)	2003-06-26	Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства
SK17142000A3 (sk)	2001-06-11	Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety
JPS60202812A (ja)	1985-10-14	ブロモクリプチン組成物